Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia

Immunology Letters

Volumn 159, Issue 1-2, 2014, Pages 76-78

  Kano, Gen ^a,b   Nakatani, Takuya ^a   Yagi, Kanae ^a   Sakamoto, Izumi ^a   Imamura, Toshihiko ^b  

^a Kobe College   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; ETOPOSIDE; HERPES ZOSTER IMMUNOGLOBULIN; IFOSFAMIDE; IMMUNOGLOBULIN G; PREDNISOLONE; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; BIOPSY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CERVICAL LYMPHADENOPATHY; CHEMOTHERAPY; CHILD; CLINICAL FEATURE; CYTOKINE STORM; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HISTIOCYTE; HISTOLOGY; HUMAN; HYPERCALCEMIA; IMMUNOGLOBULIN DEFICIENCY; KIKUCHI DISEASE; LARGE CELL LYMPHOMA; LETTER; LYMPH NODE HYPERPLASIA; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RITUXIMAB INDUCED PERSISTENT HYPOGAMMAGLOBULINEMIA; SALVAGE THERAPY; SCHOOL CHILD; SCINTIGRAPHY; SPLENOMEGALY; THERAPY DELAY; TONSILLECTOMY; AGAMMAGLOBULINEMIA; B LYMPHOCYTE; CHEMICALLY INDUCED; COMPLICATION; IMMUNOLOGY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATHOLOGY;

ADOLESCENT; AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; FEMALE; HISTIOCYTIC NECROTIZING LYMPHADENITIS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE;

EID: 84899624881     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.10.005     Document Type: Letter

References (7)

1. Gea-Banacloche J.C. Rituximab-associated infections. Seminars in Hematology 2010, 47:187-198.
2. Hicks L.K., Woods A., Buckstein R., Mangel J., Pennell N., Zhang L., et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplantation 2009, 43:701-708.
3. De La Torre I., Leandro M.J., Valor L., Becerra E., Edwards J.C.W., Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology 2012, 51:833-840.
4. Nishio M., Fujimoto K., Yamamoto S., Endo T., Sakai T., Obara M., et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. European Journal of Haematology 2006, 77:226-232.
5. Cramer J., Schmiedel S., Alegre N.G., Schäfer H., Burchard G.D., Merz H. Necrotizing lymphadenitis: Kikuchi-Fujimoto disease alias lupus lymphadenitis?. Lupus 2010, 19:89-92.
6. Wehr C., Kivioja T., Schmitt C., Ferry B., Witte T., Eren E., et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008, 111:77-85.
7. Driessen G.J., van Zelm M.C., van Hagen P.M., Hartwig N.G., Trip M., Warris A., et al. B-cell replication history and somatic hypermutation status identify distinct pathophysiologic backgrounds in common variable immunodeficiency. Blood 2011, 118:6814-6823.